SEPN Septerna, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1984086 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY336.7%
TTM net income YoY-0.3%
TTM EPS YoY-109.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-76.2%
Net margin-61.3%
FCF margin-80.6%
EBITDA margin-74.6%
Returns
ROE-14.4%
ROA-9.6%
ROIC (approx.)-35.2%
Asset turnover0.16x
Leverage & solvency
Liabilities / assets30.9%
Debt / equity0.00x
Current ratio4.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.30x
Accruals ratio2.9%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $45.95M | $1.07M | $151,000 |
| R&D expense | $97.58M | $65.34M | $35.98M |
| SG&A expense | $29.16M | $16.56M | $9.72M |
| Operating income | -$68.30M | -$80.82M | $2.08M |
| Pretax income | -$48.87M | -$72.30M | -$48.87M |
| Income tax | $12,000 | -$498,000 | $691,000 |
| Net income | -$48.88M | -$71.80M | $4.18M |
| EBITDA | -$66.70M | -$79.42M | $2.88M |
| EPS (basic) | -1.10 | -7.26 | 0.29 |
| EPS (diluted) | -1.10 | -7.26 | 0.29 |
| Weighted avg. shares (diluted) | 44.26M | 9.89M | 2.18M |
| Balance sheet | |||
| Cash & equivalents | $120.72M | $238.20M | $88.48M |
| Short-term investments | $270.37M | $112.73M | $0 |
| Receivables | $10.36M | $171,000 | $151,000 |
| Current assets | $410.96M | $356.82M | $112.68M |
| PP&E, net | $4.43M | $5.09M | $4.67M |
| Total assets | $596.19M | $456.55M | $130.87M |
| Current liabilities | $86.93M | $12.85M | $6.91M |
| Total liabilities | $214.26M | $36.51M | $20.03M |
| Shareholders' equity | $381.93M | $420.05M | -$38.37M |
| Shares outstanding | 44.81M | 44.42M | 3.17M |
| Cash flow statement | |||
| Operating cash flow | $110.19M | -$67.47M | -$38.72M |
| Capital expenditure | $518,000 | $2.10M | $2.88M |
| Free cash flow | $109.67M | -$69.57M | -$41.60M |
| Investing cash flow | -$229.35M | -$160.60M | $22.12M |
| Financing cash flow | $1.69M | $377.78M | $74.52M |
| Depreciation & amortization | $1.60M | $1.40M | $800,000 |
| Stock-based compensation | $8.48M | $3.15M | $1.62M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.